Geode Capital Management LLC Increases Stock Position in OrthoPediatrics Corp. (NASDAQ:KIDS)

Geode Capital Management LLC lifted its holdings in shares of OrthoPediatrics Corp. (NASDAQ:KIDS) by 0.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 392,274 shares of the company’s stock after purchasing an additional 782 shares during the period. Geode Capital Management LLC owned about 1.62% of OrthoPediatrics worth $9,095,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Wellington Management Group LLP increased its position in OrthoPediatrics by 20.2% during the fourth quarter. Wellington Management Group LLP now owns 1,061,299 shares of the company’s stock worth $24,601,000 after buying an additional 178,078 shares in the last quarter. Triodos Investment Management BV boosted its stake in shares of OrthoPediatrics by 29.2% during the fourth quarter. Triodos Investment Management BV now owns 93,000 shares of the company’s stock valued at $2,156,000 after acquiring an additional 21,000 shares during the last quarter. JPMorgan Chase & Co. increased its position in OrthoPediatrics by 204.8% during the 4th quarter. JPMorgan Chase & Co. now owns 42,817 shares of the company’s stock worth $992,000 after purchasing an additional 28,768 shares in the last quarter. EntryPoint Capital LLC acquired a new position in OrthoPediatrics in the 4th quarter valued at about $528,000. Finally, KLP Kapitalforvaltning AS purchased a new position in OrthoPediatrics in the 4th quarter valued at about $79,000. 69.05% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other OrthoPediatrics news, insider Gregory A. Odle sold 5,359 shares of the business’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $133,224.74. Following the transaction, the insider now owns 148,788 shares in the company, valued at $3,698,869.68. The trade was a 3.48 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO David R. Bailey sold 6,620 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $164,573.20. Following the sale, the chief executive officer now owns 319,155 shares of the company’s stock, valued at $7,934,193.30. This represents a 2.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,732 shares of company stock worth $589,978 in the last 90 days. 31.80% of the stock is owned by company insiders.

OrthoPediatrics Stock Performance

NASDAQ:KIDS opened at $20.77 on Thursday. The company has a market cap of $504.44 million, a P/E ratio of -16.89 and a beta of 1.17. The company has a quick ratio of 3.68, a current ratio of 7.17 and a debt-to-equity ratio of 0.19. The firm’s 50 day moving average is $23.63 and its two-hundred day moving average is $24.47. OrthoPediatrics Corp. has a fifty-two week low of $20.26 and a fifty-two week high of $35.99.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.04. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. The firm had revenue of $52.67 million for the quarter, compared to analyst estimates of $51.16 million. During the same quarter last year, the firm posted ($0.23) earnings per share. Analysts expect that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on KIDS shares. Stifel Nicolaus cut their price objective on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, March 5th. Truist Financial cut their price target on OrthoPediatrics from $26.00 to $24.00 and set a “hold” rating for the company in a report on Friday, April 11th. Needham & Company LLC reissued a “buy” rating and set a $42.00 price target on shares of OrthoPediatrics in a research note on Wednesday, April 9th. Finally, Lake Street Capital assumed coverage on OrthoPediatrics in a research report on Monday, April 7th. They issued a “buy” rating and a $37.00 price objective for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $37.00.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.